Cheryl Vallie, NP
Family · Midland, TXNPI 1417941410
Payments from drug & device makers
Across 343 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$526
- GSK$508
- Amgen$403
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,309100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $1,507 |
| Novo Nordisk | 61 | $1,425 |
| AstraZeneca(2 entities) | 31 | $1,233 |
| Lilly USA, LLC | 34 | $526 |
| GSK | 15 | $508 |
| Amgen(2 entities) | 14 | $403 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $397 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $220 |
| Boehringer Ingelheim | 8 | $205 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $203 |
| Idorsia Pharmaceuticals US Inc | 9 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $173 |
| Pfizer | 9 | $154 |
| Abbott | 4 | $141 |
| Sanofi-aventis U.S. LLC | 7 | $133 |
| Alkermes, Inc. | 4 | $130 |
| Biohaven Pharmaceuticals, Inc. | 14 | $120 |
| Vanda Pharmaceuticals Inc. | 5 | $96 |
| Exeltis, USA Inc. | 1 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Antares Pharma, Inc. | 3 | $52 |
| Tactile Systems Technology Inc | 2 | $47 |
| Bayer | 2 | $43 |
| Johnson & Johnson | 2 | $41 |
| Novartis | 2 | $39 |
| Exact Sciences | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $29 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Vivus LLC | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
| Genentech USA, Inc. | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$210
- CAPLYTA$157
- TRELEGY ELLIPTA$125
- Ozempic$124
- Saxenda$119
- Otezla$109
- FreeStyle Libre$108
- NUCALA$106
How this compares
$8,309 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $52,947 |
| TrulicityDulaglutide | 38 | $36,236 |
| MounjaroTirzepatide | 34 | $34,733 |
| JardianceEmpagliflozin | 23 | $27,928 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $27,338 |
| RybelsusSemaglutide | 23 | $25,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $21,121 |
| FarxigaDapagliflozin Propanediol | 19 | $19,939 |
| EliquisApixaban | 23 | $17,009 |
| GlyxambiEmpagliflozin/Linagliptin | 19 | $16,791 |
| QuliptaAtogepant | 13 | $13,960 |
| MyrbetriqMirabegron | 19 | $8,678 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $7,195 |
| Colesevelam Hcl | 12 | $5,568 |
| VascepaIcosapent Ethyl | 17 | $4,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,425 | $78,64959 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $526 | $70,96972 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy | $205 | $51,91455 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,233 | $47,27758 claims |
| GSKTrelegy Ellipta | $508 | $21,12131 claims |
| AbbVieQulipta, Synthroid | $1,507 | $17,91764 claims |
| PfizerEliquis | $154 | $17,00923 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $8,67819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Midland
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.